Search

Displaying results 3501 - 3510 of 7706 in total
  1. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).

  2. Drug

    Bermekimab

    go.drugbank.com/drugs/DB14947
    Investigational

    Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).

    Synonyms: RA-18C3
  3. Drug

    CH-1504 L-isomer

    go.drugbank.com/drugs/DB19052
    Investigational

    CH-1504 L-isomer is under investigation in clinical trial NCT01116141 (A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)).

  4. Drug

    Ambrosia artemisiifolia pollen

    go.drugbank.com/drugs/DB10385
    Approved

    Ambrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.

  5. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.

  6. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor

  7. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

  8. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.

  9. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vac...

    Mixtures: Dt Polio Adsorbed - Sus Im
  10. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.